PT97423A - Processo para a preparacao de composicoes farmaceuticas contendo conjugados de anticorpos para o tratamento de neoplasias - Google Patents
Processo para a preparacao de composicoes farmaceuticas contendo conjugados de anticorpos para o tratamento de neoplasiasInfo
- Publication number
- PT97423A PT97423A PT97423A PT9742391A PT97423A PT 97423 A PT97423 A PT 97423A PT 97423 A PT97423 A PT 97423A PT 9742391 A PT9742391 A PT 9742391A PT 97423 A PT97423 A PT 97423A
- Authority
- PT
- Portugal
- Prior art keywords
- neoplasms
- treatment
- pharmaceutical compositions
- compositions containing
- preparing pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6821—Plant heterodimeric toxins, e.g. abrin or modeccin
- A61K47/6823—Double chain ricin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51092390A | 1990-04-19 | 1990-04-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT97423A true PT97423A (pt) | 1992-01-31 |
| PT97423B PT97423B (pt) | 1998-10-30 |
Family
ID=24032743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97423A PT97423B (pt) | 1990-04-19 | 1991-04-19 | Processo para a preparacao de composicoes farmaceuticas contendo conjugados de anticorpos para o tratamento de neoplasias |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20050214307A1 (pt) |
| EP (1) | EP0525119B1 (pt) |
| JP (1) | JP3340127B2 (pt) |
| KR (1) | KR100212372B1 (pt) |
| CN (1) | CN1071579C (pt) |
| AT (1) | ATE164078T1 (pt) |
| AU (1) | AU650267B2 (pt) |
| CA (1) | CA2079902C (pt) |
| DE (1) | DE69129109T2 (pt) |
| DK (1) | DK0525119T3 (pt) |
| ES (1) | ES2113376T3 (pt) |
| FI (1) | FI104234B (pt) |
| HK (1) | HK1008418A1 (pt) |
| IE (1) | IE62496B1 (pt) |
| IL (1) | IL97776A (pt) |
| NO (1) | NO317485B1 (pt) |
| NZ (1) | NZ237688A (pt) |
| PT (1) | PT97423B (pt) |
| RU (1) | RU2119352C1 (pt) |
| SA (1) | SA91120208B1 (pt) |
| TW (1) | TW211573B (pt) |
| WO (1) | WO1991016071A1 (pt) |
| ZA (1) | ZA912490B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750329B1 (en) * | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
| CA2072249C (en) * | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| US6787153B1 (en) | 1991-06-28 | 2004-09-07 | Mitsubishi Chemical Corporation | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| US5632982A (en) * | 1994-06-07 | 1997-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Cytotoxic enhancement of TNF with copper |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| JP2004535202A (ja) | 2001-07-17 | 2004-11-25 | リサーチ ディベロップメント ファンデーション | アポトーシス促進性蛋白質を含む治療剤 |
| US20040013691A1 (en) * | 2002-06-12 | 2004-01-22 | Rosenblum Michael G. | Immunotoxin as a therapeutic agent and uses thereof |
| JP4989850B2 (ja) * | 2002-10-25 | 2012-08-01 | アメリカ合衆国 | ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法 |
| JP2008528633A (ja) * | 2005-02-01 | 2008-07-31 | リサーチ ディベロップメント ファウンデーション | Ｂｌｙｓレセプターを標的化するためのｂｌｙｓ融合タンパク質およびｂ細胞増殖性疾患の処置方法 |
| EP1861123A2 (en) * | 2005-02-17 | 2007-12-05 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Synergistic efect of tgf-beta blockade and immunogenic agents on tumors |
| WO2007109193A2 (en) * | 2006-03-16 | 2007-09-27 | Health Research Inc. | Inhibition of breast carcinoma stem cell growth and metastasis |
| SG11201407106XA (en) | 2012-05-01 | 2014-11-27 | Genentech Inc | Anti-pmel17 antibodies and immunoconjugates |
| US10071170B2 (en) | 2013-06-24 | 2018-09-11 | Ablbio | Antibody-drug conjugate having improved stability and use thereof |
| RU2689689C2 (ru) | 2015-01-23 | 2019-05-28 | Хеликс Байофарма Корпорейшн | Конъюгаты антитело-уреаза для терапевтических целей |
| MY195280A (en) | 2017-09-08 | 2023-01-12 | New Portal Ltd | Nucleic Acid Systems That Enable Bacteria to Specifically Target Solid Tumors Via Glucose-Dependent Viability |
| CN110455903A (zh) * | 2018-05-07 | 2019-11-15 | 天士力生物医药股份有限公司 | 一种注射用重组人尿激酶原杂质分析的梯度电泳检测方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4263279A (en) * | 1975-08-19 | 1981-04-21 | Yeda Research & Development Co. Ltd | Pharmaceutically active compositions containing adriamycin and daunomycin |
| FR2504010B1 (fr) * | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4522918A (en) * | 1981-12-15 | 1985-06-11 | Jeffery Schlom | Process for producing monoclonal antibodies reactive with human breast cancer |
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| FR2546756B1 (fr) * | 1983-06-03 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux derives immunostimulants, leur preparation et leur application comme medicament |
| US4894443A (en) * | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
| US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| FR2566271B1 (fr) * | 1984-06-20 | 1986-11-07 | Sanofi Sa | Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention |
| US4650674A (en) * | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
| US4590071A (en) * | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
| US4677064A (en) * | 1984-11-09 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US5032521A (en) * | 1984-12-05 | 1991-07-16 | The Salk Institute For Biological Studies | Monoclonal antibody specific for a mammary tumor cell surface antigen |
| US4888415A (en) * | 1985-03-04 | 1989-12-19 | Dana-Farber Cancer Institute, Inc. | Gelonin immunotoxin |
| US6084073A (en) * | 1985-03-25 | 2000-07-04 | Chiron Corporation | Recombinant ricin toxin |
| US4870163A (en) * | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
| US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4962188A (en) * | 1985-12-06 | 1990-10-09 | Cetus Corporation | Recombinant ricin toxin A chain conjugates |
| US4831122A (en) * | 1986-01-09 | 1989-05-16 | Regents Of The University Of Minnesota | Radioimmunotoxins |
| US4894227A (en) * | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4771128A (en) * | 1986-10-10 | 1988-09-13 | Cetus Corporation | Method of purifying toxin conjugates using hydrophobic interaction chromatography |
| US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| US4963354A (en) * | 1987-01-21 | 1990-10-16 | Genentech, Inc. | Use of tumor necrosis factor (TNF) as an adjuvant |
| US4894225A (en) * | 1987-03-02 | 1990-01-16 | Cetus Corporation | Combination therapy using antitumor immunotoxins with tumor necrosis factor |
| US4863726A (en) * | 1987-05-29 | 1989-09-05 | Cetus Corporation | Combination therapy using immunotoxins with interleukin-2 |
| US5017371A (en) * | 1988-01-06 | 1991-05-21 | Amarillo Cell Culture Company, Incorporated | Method for reducing side effects of cancer therapy |
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| IE62463B1 (en) * | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
| US5134075A (en) * | 1989-02-17 | 1992-07-28 | Oncogen Limited Partnership | Monoclonal antibody to novel antigen associated with human tumors |
| IE63847B1 (en) * | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US6750329B1 (en) * | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
| US6306626B1 (en) * | 1990-04-27 | 2001-10-23 | Research Development Foundation | Anti-IgM monoclonal antibodies and methods of their use |
| IE912716A1 (en) * | 1990-08-14 | 1992-02-26 | Res Dev Foundation | Protein Structure of the Plant Toxin Gelonin |
| US6099842A (en) * | 1990-12-03 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin |
| ES2096749T3 (es) * | 1990-12-14 | 1997-03-16 | Cell Genesys Inc | Cadenas quimericas para vias de transduccion de señal asociada a un receptor. |
| US5621083A (en) * | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US5837491A (en) * | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
| US6599505B1 (en) * | 1992-04-10 | 2003-07-29 | Research Development Foundation | Immunotoxins directed against CD33 related surface antigens |
| IL112372A (en) * | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
| US5513296A (en) * | 1994-06-08 | 1996-04-30 | Holmes Products Corp. | Air heater with angled PTC heaters producing diverging heated airflow |
| WO1999051620A1 (en) * | 1998-04-03 | 1999-10-14 | Invitrogen Corporation | Libraries of expressible gene sequences |
| US20030186384A1 (en) * | 2000-04-22 | 2003-10-02 | Stefan Barth | Apoptotic agents |
| ZA200305980B (en) * | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| JP2004535202A (ja) * | 2001-07-17 | 2004-11-25 | リサーチ ディベロップメント ファンデーション | アポトーシス促進性蛋白質を含む治療剤 |
| US20040013691A1 (en) * | 2002-06-12 | 2004-01-22 | Rosenblum Michael G. | Immunotoxin as a therapeutic agent and uses thereof |
-
1991
- 1991-04-04 IE IE112291A patent/IE62496B1/en not_active IP Right Cessation
- 1991-04-04 IL IL9777691A patent/IL97776A/xx not_active IP Right Cessation
- 1991-04-04 NZ NZ237688A patent/NZ237688A/xx unknown
- 1991-04-04 ZA ZA912490A patent/ZA912490B/xx unknown
- 1991-04-12 TW TW080102833A patent/TW211573B/zh active
- 1991-04-19 AU AU78922/91A patent/AU650267B2/en not_active Ceased
- 1991-04-19 EP EP91909732A patent/EP0525119B1/en not_active Expired - Lifetime
- 1991-04-19 DE DE69129109T patent/DE69129109T2/de not_active Expired - Fee Related
- 1991-04-19 WO PCT/US1991/002696 patent/WO1991016071A1/en active IP Right Grant
- 1991-04-19 CA CA002079902A patent/CA2079902C/en not_active Expired - Fee Related
- 1991-04-19 RU RU92016354A patent/RU2119352C1/ru not_active IP Right Cessation
- 1991-04-19 JP JP50922891A patent/JP3340127B2/ja not_active Expired - Fee Related
- 1991-04-19 CN CN91102606A patent/CN1071579C/zh not_active Expired - Fee Related
- 1991-04-19 ES ES91909732T patent/ES2113376T3/es not_active Expired - Lifetime
- 1991-04-19 PT PT97423A patent/PT97423B/pt not_active IP Right Cessation
- 1991-04-19 KR KR1019920702569A patent/KR100212372B1/ko not_active IP Right Cessation
- 1991-04-19 AT AT91909732T patent/ATE164078T1/de not_active IP Right Cessation
- 1991-04-19 DK DK91909732T patent/DK0525119T3/da active
- 1991-10-23 SA SA91120208A patent/SA91120208B1/ar unknown
-
1992
- 1992-10-12 FI FI924605A patent/FI104234B/fi not_active IP Right Cessation
- 1992-10-16 NO NO19924025A patent/NO317485B1/no unknown
-
1998
- 1998-07-14 HK HK98109132A patent/HK1008418A1/xx not_active IP Right Cessation
-
2004
- 2004-08-26 US US10/926,731 patent/US20050214307A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT97423A (pt) | Processo para a preparacao de composicoes farmaceuticas contendo conjugados de anticorpos para o tratamento de neoplasias | |
| DE3852250T2 (de) | Über Thioetherbindungen verknüpfte Immunokonjugate, mit verminderter Toxizität und vermehrter Selektivität. | |
| JP5926759B2 (ja) | 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法 | |
| CA1318615C (en) | Radiohalogenated compounds for site specific labeling | |
| NO885199D0 (no) | Fremgangsmte for fremstilling av monoklonale antistoffkonjugater. | |
| HK1155070A1 (en) | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders -cd70 - | |
| BRPI0615049A2 (pt) | processo para a preparação de conjugados de medicamento purificado | |
| ES544846A0 (es) | Un procedimiento para preparar una composicion citotoxica | |
| GR1000712B (el) | Νεα αντισωματα που αντιδρουν με τα ανθρωπινα καρκινωματα. | |
| DE3687736D1 (de) | Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung. | |
| RU92016354A (ru) | Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата | |
| DE3686313D1 (de) | Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung. | |
| ATE162403T1 (de) | Modifizierte antikörper mit kontrollierter clearance-zeit | |
| BG42837A3 (en) | Method for preparing immunoglobulin derivatives of vinka alkaloides | |
| PT81093B (pt) | Processo para a preparacao de uma composicao terapeutica para tratamento de um tumor | |
| ES556684A0 (es) | Un procedimiento para tratar celulas efectoras que tienen receptores de superficie para la region fc de un anticuerpo | |
| ES2121881T3 (es) | Anticuerpos monoclonales anti-gangliosidos, su preparacion y su empleo como agente terapeutico de tumores. | |
| WO2004041307A3 (en) | Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy | |
| EA200100311A1 (ru) | Бифункциональные антитела и их применение для прицельной доставки противоопухолевых средств | |
| PT100660A (pt) | Compostos conjugados uteis para o tratamento de tumores gastrointestinais e composicoes farmaceuticas que os contem | |
| TWI265811B (en) | Extended type 1 chain glycosphingolipids as tumor-associated antigens | |
| NO951061L (no) | Antistoffkonjugater med forbedrede egenskaper |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Laying open of patent application |
Effective date: 19910912 |
|
| FG3A | Patent granted, date of granting |
Effective date: 19980724 |
|
| MM4A | Annulment/lapse due to non-payment of fees, searched and examined patent |
Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20090126 |